Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-132861 · Präparat HOS-097310

Monitoring of QT-prolongation if used concomitantly. Bortezomib Bortezomib: Careful monitoring. Busulfan AUC: ↑ 1.4-fold Dose adjustment of each medicinal Docetaxel Imatinib: product may be required. Imatinib AUC: ↑ 1.4-fold Cabazitaxel Cmax: ↑ 1.3-fold ↑in plasma concentrations of docetaxel have been observed Potential ↑in plasma concentrations of busulfan Cabazitaxel AUC: ↑ 1.3-fold Paclitaxel Paclitaxel: Careful monitoring. No change in plasma concentration were Dose adjustment of paclitaxel shown with paclitaxel concentrate. No may be required. studies were performed with albumin bound nanoparticules. Vincristine, vinblastine Potential ↑in plasma concentrations of Careful monitoring as it may cause (vinca alkaloids) vinca alkaloids. an earlier onset and/or an increased severity of side-effects. Antipsychotics, Anxiolytics and Hypnotics Triazolam AUC: ↑ have been observed Contraindicated due to the risk of Alprazolam Cmax: ↑ have been observed potentially prolonged or increased Midazolam oral sedation and respiratory depression (see section 4.3). Lurasidone Lurasidone: Contraindicated due to the increased AUC: ↑ 9 fold risk of adverse reactions (see section Cmax: ↑ 6 fold 4.3). Pimozide Potential ↑in plasma concentrations of Contraindicated due to the risk of pimozide. serious cardiovascular events including QT prolongation (see section 4.3). Sertindole Potential ↑in plasma concentrations of Contraindicated due to the risk of QT sertindole. prolongation (see section 4.3). Quetiapine Quetiapine: Contraindicated as it may increase AUC: ↑ 6.2-fold quetiapine-related toxicity (see Cmax: ↑ 3.4-fold section 4.3). Haloperidol Potential ↑in plasma concentrations of Not recommended due to the haloperidol. increased risk of QT prolongation and extrapyramidal symptoms. It may be necessary to reduce haloperidol dosage. Reboxetine Reboxetine: Not recommended because of AUC: ↑ 1.5-fold of both enantiomers reboxetine narrow’s therapeutic margin. Midazolam IV Midazolam: Careful monitoring. AUC: ↑ 1.6-fold Dose adjustment of midazolam IV may be required. 11 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration Buspirone Potential ↑in plasma concentrations of Careful monitoring. buspirone. Dose adjustement of buspirone may be required. Aripiprazole Aripiprazole Careful monitoring. AUC: ↑ 1.6-fold Aripiprazole dose should be reduced Cmax: ↑ 1.4-fold to approximatively one-half of its prescribed dose. Risperidone Potential ↑in AUC of risperidone: Careful monitoring. Dose adjustment of risperidone may be required. Antivirals products Saquinavir Saquinavir: Contraindicated due to the risk of QT (saquinavir/ritonavir AUC: ↔ prolongation (see section 4.3). 1000/100 mg bid) Cmax: ↔ Ketoconazole AUC: ↑ 2.7-fold Cmax:↑ 1.5-fold (CYP3A4 enzyme inhibition by ritonavir) Paritaprevir: Contraindicated due to the increased AUC: ↑2.2-fold risk of adverse reactions (see section Cmax: ↑1.7-fold 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aripiprazole (HOS-129408) sertindole (HOS-085601) quetiapine (HOS-086150) busulfan (HOS-115553) reboxetine (HOS-132863) alprazolam (HOS-086171) vinblastine (HOS-086220) risperidone (HOS-086280) vincristine (HOS-086219) imatinib (HOS-110212) docetaxel (HOS-084505) saquinavir (HOS-084522) bortezomib (HOS-110227) pimozide (HOS-085600) cabazitaxel (HOS-124028) buspirone (HOS-086325) paclitaxel (HOS-087959) haloperidol (HOS-085602) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)